<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349697</url>
  </required_header>
  <id_info>
    <org_study_id>BIOT1200</org_study_id>
    <nct_id>NCT03349697</nct_id>
  </id_info>
  <brief_title>Phyllantus Amarus for the Protection of Liver Health</brief_title>
  <official_title>Phyllantus Amarus for the Protection of Liver Health: A Randomized, Double Blind, Placebo Controlled Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotropics Malaysia Berhad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotropics Malaysia Berhad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo controlled crossover study. The purpose of&#xD;
      this study is to assess the ability of Phyllantus amarus to protect the liver against&#xD;
      temporary stress including oxidative stress induced by alcohol consumption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2010</start_date>
  <completion_date type="Actual">October 16, 2010</completion_date>
  <primary_completion_date type="Actual">October 16, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on HS CRP levels in blood</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on the inflammatory cytokines in blood</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on liver function levels in blood</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on glutatoine peroxidase (GSH-Px) in blood</measure>
    <time_frame>26 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on hangover severity score</measure>
    <time_frame>26 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on profile of mood states (POMS)</measure>
    <time_frame>26 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on cognitive performance tests</measure>
    <time_frame>26 days</time_frame>
    <description>Using the CNS Vital Signs System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on sleep quality</measure>
    <time_frame>26 days</time_frame>
    <description>Based on the number of hours slept</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on adverse events</measure>
    <time_frame>36 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on a comprehensive metabolic panel (CMP) analysis</measure>
    <time_frame>26 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on complete blood count</measure>
    <time_frame>26 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Compare the effect of Phyllantus versus placebo on Urinalaysis</measure>
    <time_frame>26 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Active Product then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Active Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Phyllantus amarus</intervention_name>
    <arm_group_label>Active Product then Placebo</arm_group_label>
    <arm_group_label>Placebo then Active Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Active Product then Placebo</arm_group_label>
    <arm_group_label>Placebo then Active Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female 21-50 years of age, inclusive.&#xD;
&#xD;
          -  Subject consumes at least 5 servings of alcohol per week on a regular basis.&#xD;
&#xD;
          -  Minimum POMS score of 15.&#xD;
&#xD;
          -  Access to a computer and internet&#xD;
&#xD;
          -  Subject is willing to maintain his or her habitual food and beverage intake (other&#xD;
             than substitution of study food for similar products) and physical activity patterns&#xD;
             throughout the study period.&#xD;
&#xD;
          -  Body mass index (BMI) between 20 and 30 kg/m2.&#xD;
&#xD;
          -  Subject is willing and able to comply with the alcohol consumption requirements.&#xD;
&#xD;
          -  Subjects willing to stay in the clinic for two overnight stays&#xD;
&#xD;
          -  Judged by the Investigator to be in general good health on the basis of medical&#xD;
             history.&#xD;
&#xD;
          -  Subject understands the study procedures and signs forms providing informed consent to&#xD;
             participate in the study and authorization for release of relevant protected health&#xD;
             information to the study investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any Liver condition including Hepatitis, Fatty Liver, Liver Disease.&#xD;
&#xD;
          -  Liver Function greater than three times the upper level limit of normal&#xD;
&#xD;
          -  History or record of aggressive or violent behavior&#xD;
&#xD;
          -  Any significant GI condition that would potentially interfere with the evaluation of&#xD;
             the study product [e.g., Ulcerative Colitis or Crohn's Disease, inflammatory bowel&#xD;
             disease, irritable bowel syndrome, Clinically significant Gastritis, history of upper&#xD;
             GI bleed (bleeding ulcer), chronic constipation (defined as &lt;3 bowel movements per&#xD;
             week), history of frequent diarrhea, history of surgery for weight loss,&#xD;
             gastroparesis, clinically important lactose intolerance].&#xD;
&#xD;
          -  Clinically significant renal, hepatic, endocrine (including diabetes mellitus),&#xD;
             cardiac, pulmonary, pancreatic, neurologic, or biliary disorder.&#xD;
&#xD;
          -  Known allergy or sensitivity to any ingredients in the study products.&#xD;
&#xD;
          -  Extreme dietary habits (e.g., vegan, Atkins Diet, etc.).&#xD;
&#xD;
          -  Recent (within two weeks of visit 1, week -1) episode of acute gastrointestinal&#xD;
             illness such as nausea, vomiting, or diarrhea.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure _160 mm Hg or diastolic blood&#xD;
             pressure _100 mm Hg at visit 1, week -1).&#xD;
&#xD;
          -  History or presence of cancer in the prior two years, except for non-melanoma skin&#xD;
             cancer.&#xD;
&#xD;
          -  Any major trauma or surgical event within three months of visit 1, week -1.&#xD;
&#xD;
          -  Recent use of antibiotics (within 6 weeks).&#xD;
&#xD;
          -  Females who are pregnant, lactating, planning to be pregnant during the study period.&#xD;
&#xD;
          -  Recent history of (within 12 months) or strong potential for alcohol or substance&#xD;
             abuse. Alcohol abuse will be defined as &gt;14 drinks per week (1 drink =12 ounces beer,&#xD;
             5 ounces wine, or 1 Â½ ounces distilled spirits).&#xD;
&#xD;
          -  Participation in a clinical study with exposure to any non-registered drug product&#xD;
             within 30 days prior.&#xD;
&#xD;
          -  Individual has a condition the Investigator believes would interfere with his or her&#xD;
             ability to provide informed consent, comply with the study protocol, which might&#xD;
             confound the interpretation of the study results or put the person at undue risk&#xD;
&#xD;
          -  Current active respiratory illness at the time of screening&#xD;
&#xD;
          -  Any immune system disorders&#xD;
&#xD;
          -  Subjects with a history of perforation of the stomach or intestines&#xD;
&#xD;
          -  Subjects who have had gastric bypass surgery&#xD;
&#xD;
          -  Untreated Hypothyroidism&#xD;
&#xD;
          -  Subjects with active eating disorder including anorexia nervosa, bulimia, and/or&#xD;
             obsessive compulsive eating disorders&#xD;
&#xD;
          -  Spinal cord injuries&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tengku Shahrir Tengku Adnan</last_name>
    <role>Study Director</role>
    <affiliation>Biotropics Malaysia Berhad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjay Udani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicus Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicus Research, LLC</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Health</keyword>
  <keyword>Hangover</keyword>
  <keyword>Herbal supplement</keyword>
  <keyword>Liver function</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

